En Es
Categories

Fluidigm

Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, the company develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and diseas ...
Products Covid-19Summary
Close

Covid-19 Fluidigm

Clinical Laboratory

SARS-CoV-2 RT-PCR Assay
Advanta Dx SARS-CoV-2 RT-PCR Assay

The Advanta Dx SARS-CoV-2 RT-PCR Assay is a qPCR-based test that, by taking advantage of Fluidigm proprietary microfluidics technology and the Juno and Biomark HD systems, enables reliable, high-capacity testing of saliva samples from patients suspected by their health care providers of COVID-19 (coronavirus) infection to support diagnostic decision making. The assay has been authorized for use under FDA Emergency Use Authorization (EUA) and is CE-IVD marked under the In Vitro Diagnostics Directive (IVDD 98/79/EC).
More details

RT-PCR Kit
Advanta RT-PCR Kit

The Advanta RT-PCR Kit—192.24 provides scalable, high-throughput pathogen detection through nanoliter-scale volumes with walkaway automation. Using the 192.24 Dynamic Array IFC (integrated fluidic circuit) enables rapid data acquisition of up to 192 samples across 24 targets: up to 4,608 reactions every 35 minutes. The kit enables probe-based qPCR of 1,920 samples and combines reverse transcription and preamplification in a single step.
More details

SARS-CoV-2 Mutation Assay Panel
Advanta SARS-CoV-2 Mutation Assay Panel

The Fluidigm RT-PCR based Advanta SARS-CoV-2 Mutation Assay Panel is an expansion of the Advanta pathogen detection portfolio and can concurrently detect the reference virus and mutations associated with six Variants of Concern identified by the CDC and WHO. Leveraging our proprietary microfluidics technology along with the Biomark™ HD platform and an IFC controller, the detection of these new mutations is performed seamlessly without the need for additional integrated fluidic circuits (IFCs), run reagents or sample volume, providing more data without additional labor. As the virus continues to evolve, the assay’s open design enables this solution to evolve along with it.
More details
Close

About Fluidigm

Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, the company develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Its customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide.
FaceBook Twitter Google+ Linked in
SARS-CoV-2 Mutation Assay Panel

SARS-CoV-2 Mutation Assay Panel

Model: Advanta SARS-CoV-2 Mutation Assay Panel
Request Information

Description:

The Fluidigm RT-PCR based Advanta SARS-CoV-2 Mutation Assay Panel is an expansion of the Advanta pathogen detection portfolio and can concurrently detect the reference virus and mutations associated with six Variants of Concern identified by the CDC and WHO.
Read More

Full Description Features

Description

The Fluidigm RT-PCR based Advanta SARS-CoV-2 Mutation Assay Panel is an expansion of the Advanta pathogen detection portfolio and can concurrently detect the reference virus and mutations associated with six Variants of Concern identified by the CDC and WHO. Leveraging our proprietary microfluidics technology along with the Biomark™ HD platform and an IFC controller, the detection of these new mutations is performed seamlessly without the need for additional integrated fluidic circuits (IFCs), run reagents or sample volume, providing more data without additional labor. As the virus continues to evolve, the assay’s open design enables this solution to evolve along with it. Request Information

Features

• Reflex-free workflow: Detects SARS-CoV-2 and key mutations concurrently from the same input sample on one IFC, saving reagents, samples and time
• Saliva-based and extraction-free: Performs equivalently to comparator nasal tests utilizing convenient and noninvasive sample collection without the need for commercial extraction kits
• More valuable data: Supports detection and surveillance of key mutations from a single high-throughput workflow that supports up to 6,000 samples per day
• Flexible: Enables convenient addition of mutations emerging in the future, unlike other multiplex RT-PCR assays, due to the open architecture of the IFC Request Information

Send A Message To This Supplier

* Required Information
* Email
To
Fluidigm (SARS-CoV-2 Mutation Assay Panel)
* Message

Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions